Department of Gastroenterology and Hepatology, Iwate Medical University Department of Welfare Engineering, Faculty of Engineering, Iwate University Department of Pathology, Iwate Medical University School of Medicine, Morioka Immunology Frontier Research Center, Osaka University, Osaka Research and Development Center, Nagase, Tokyo, Japan.
Hepatol Res. 2011 Jan;41(1):87-92. doi: 10.1111/j.1872-034X.2010.00747.x.
Carnosic acid (CA) inhibits adipogenesis in vitro. The present study evaluated the therapeutic effects of CA in ob/ob mice.
The experimental animals were given a standard chow diet with or without CA for 5 weeks. Bodyweight gain and food intake were measured during this period. Magnetic resonance imaging analysis, histological examination, serum chemistry analysis and intraperitoneal glucose tolerance test (IPGTT) were all performed.
The mice fed CA experienced significant weight loss and reduced visceral adiposity, in addition to significantly reduced serum triglyceride (TG) and cholesterol levels. Importantly, CA had a dramatic effect on the liver by reducing the hepatic TG content, thus decreasing serum alanine aminotransferase levels. In addition, IPGTT revealed that CA significantly improved glucose tolerance.
These data suggest that CA is a novel therapeutic agent for obesity-related non-alcoholic fatty liver disease.
迷迭香酸（CA）可抑制体外脂肪生成。本研究评估了 CA 在 ob/ob 小鼠中的治疗效果。
实验动物给予标准的 Chow 饮食，或在 Chow 饮食中添加 CA，持续 5 周。在此期间，测量体重增加和食物摄入量。进行磁共振成像分析、组织学检查、血清化学分析和腹腔内葡萄糖耐量试验（IPGTT）。
喂食 CA 的小鼠体重显著减轻，内脏脂肪减少，血清甘油三酯（TG）和胆固醇水平显著降低。重要的是，CA 通过降低肝 TG 含量对肝脏有显著作用，从而降低血清丙氨酸氨基转移酶水平。此外，IPGTT 显示 CA 可显著改善葡萄糖耐量。
这些数据表明，CA 是一种治疗肥胖相关非酒精性脂肪性肝病的新型治疗药物。
